BridgeBio, BMS Set Sail In Expanded SHP2 Collaboration

 
• By Alaric DeArment

Deal Snapshot: The licensing deal worth up to $905m is on top of the companies’ existing partnership to develop BBP-398 together with BMS’s PD-1 inhibitor Opdivo and shows growing pharma interest in SHP2.

BridgeBio and BMS announced an expansion to their partnership to develop SHP2 inhibitor BBP-398 • Source: Shutterstock

More from Anticancer

More from Therapy Areas